Remdesivir is an antiviral medication that is given by injection into a vein. Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.Treatment in a Medical Setting RemdesivirįDA has approved remdesivir (Veklury) for the treatment of COVID-19 in 28 days of age and older weighing at least 3 kilograms (about 7 pounds), have a positive SARS-CoV-2 viral testing result, and are: Molnupiravir is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules. People of reproductive potential who are sexually active with people of childbearing potential are advised to use a reliable method of birth control correctly and consistently during treatment with molnupiravir and for at least three months after the final dose. People of childbearing potential are advised to use a reliable method of birth control correctly and consistently during treatment with molnupiravir and for four days after the final dose. Molnupiravir is not recommended for use during pregnancy as it may cause fetal harm when administered to pregnant individuals. These errors build up over time until the virus is no longer capable of surviving. Molnupiravir tricks these enzymes into entering errors in the virus’s genetic code. Molnupiravir is an antiviral drug that works by manipulating the enzyme responsible for viral replication. Molnupiravir reduced the risk of hospitalization or death among patients with COVID-19 by 30% compared to placebo.

MolnupiravirįDA issued EUA for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults 18 and older who have tested positive for SARS-CoV-2, are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Paxlovid is not recommended for people with certain medical conditions and may interact with other prescribed medications. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is an antiviral drug that works by blocking an enzyme necessary for the replication of the virus. Paxlovid reduced the risk of hospitalization or death among patients with COVID-19 by 88% compared to placebo. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for Pfizer’s Paxlovid for the treatment of mild-to-moderate COVID-19 in people who are 12 years and older, weigh at least 40 kilograms (kg), have tested positive for SARS-CoV-2, and are at high risk for progression to severe COVID-19, including hospitalization or death. These treatments are in limited supply, and a prescription does not guarantee the medication will be available.

Drinking water to stay hydrated and getting plenty of rest can support the body’s natural defenses and help the body fight the virus. Your healthcare provider might recommend over-the-counter medications, like acetaminophen or ibuprofen, to help relieve symptoms during a COVID-19 infection. Click to find a Test to Treat location At-Home (OTC) Treatment Over-the-Counter Medications

War hospital perscriptions